Bristol Myers Squibb
Transforming Patients' Lives Through Science
About Bristol Myers Squibb
Funding & Growth
✓ Pros
- • Strong oncology portfolio
- • Good work-life balance
- • Multiple locations
- • Research investment
- • Stable company
✗ Cons
- • Post-merger integration complexity
- • Large pharma bureaucracy
- • Revlimid patent cliff impact
🏢 Working Here
Bristol Myers Squibb (BMS) operates major computational biology centers in Cambridge, MA (Kendall Square, housing the Informatics and Predictive Sciences department), Summit, NJ, and San Diego, CA.
The 2019 Celgene merger created one of the largest oncology/immunology portfolios in pharma.
The Cambridge location provides access to the exceptional Boston biotech ecosystem and academic collaborations with Harvard, MIT, and Dana-Farber.
Bioinformaticians work on leading programs: Opdivo/Yervoy (checkpoint inhibitors), Revlimid (multiple myeloma), CAR-T therapies (Breyanzi, Abecma), and cardiovascular drugs.
The Informatics and Predictive Sciences (IPS) department conducts computational research in genomics, structural informatics, systems biology, translational biomarkers, and machine learning across drug discovery and development.
Teams are highly specialized by therapeutic area.
The culture post-merger emphasizes innovation and speed with pharma rigor.
Work involves analyzing clinical trial data, developing predictive biomarkers, and integrating real-world evidence.
The Cambridge location commands premium salaries and attracts top computational talent.
🧬 Bioinformatics Focus
BMS computational biology focuses on immuno - oncology and hematology. Core areas:
- Cancer immunotherapy - analyzing tumor microenvironment, developing combination therapy biomarkers for Opdivo/Yervoy, predicting checkpoint inhibitor response,
- CAR - T cell therapy - analyzing patient samples from Breyanzi and Abecma trials, understanding CAR-T expansion and persistence, predicting cytokine release syndrome risk,
- Multiple myeloma - genomic analysis of Revlimid and novel therapies, understanding resistance mechanisms,
- Single - cell immunoprofiling - deep characterization of immune responses using scRNA-seq, CyTOF, and spatial transcriptomics,
- Translational biomarkers - moving discoveries from research to FDA-approved companion diagnostics. BMS has pioneered work in tumor mutational burden (TMB) as a biomarker and maintains collaborations with Foundation Medicine for comprehensive genomic profiling. The Celgene acquisition brought expertise in hematologic malignancies and real-world data analytics. Technical challenges include analyzing complex combination therapies, integrating multi-modal immune profiling data, and developing biomarkers that work across multiple cancer types.
📈 Career Growth & Development
Career Paths
Scientific Track
Leadership Track
Compensation
Competitive compensation includes 15-20% annual bonuses, stock grants, and comprehensive benefits. The Cambridge location offers premium salaries.
Development
Professional development includes BMS University internal programs, external courses, and conference attendance. The company supports publications and academic collaborations.
Mobility
Many scientists gain deep expertise and transition to other companies or faculty positions. Post-merger, there are abundant opportunities as the company integrates capabilities.
Network
The BMS alumni network is strong, particularly in the oncology and immunology sectors.
Culture
The company values both deep expertise in therapeutic areas and cross-functional collaboration.
Expertise
BMS scientists gain deep expertise in immuno-oncology, a growing and important field.
💊 Top Medicines & Blockbuster Drugs
Opdivo (nivolumab)
2014Indication: Cancer immunotherapy - lung, kidney, melanoma, head & neck cancers
PD-1 checkpoint inhibitor
Annual Revenue (USD)
Eliquis (apixaban)
2012Indication: Blood thinner - stroke prevention in atrial fibrillation
World's top-selling oral anticoagulant
Annual Revenue (USD)
Revlimid (lenalidomide)
2005Indication: Multiple myeloma and blood cancers
Celgene acquisition - lost exclusivity 2022
Annual Revenue (USD)
Abecma (ide-cel)
2021Indication: CAR-T therapy for relapsed/refractory multiple myeloma
First BCMA-targeted CAR-T
Annual Revenue (USD)
Breyanzi (lisocabtagene maraleucel)
2021Indication: CAR-T therapy for large B-cell lymphoma
Differentiated manufacturing
Annual Revenue (USD)